The phase 3 trial was evaluating two doses of anti-LAG-3 antibody fianlimab in combination with PD-1 inhibitor Libtayo (cemiplimab) as a first-line treatment in more than 1,500 patients with unresectable locally advanced or metastatic melanoma, comparing the regimen to monotherapy with MSD's widely-used PD-1 drug Keytruda (pembrolizumab)
The Role of Personalized Support Every body reacts differently to weight loss medications
In their view, compounded versions are not the same as the FDA-approved products (Ozempic, Wegovy, Rybelsus) and have not undergone the same rigorous testing for safety, efficacy, and manufacturing quality
Trends in Usage and Payments for Glucagon-Like Peptide-1 Receptor Agonists in the United States, 2017 to 2022: A Nationally Representative Repeated Cross-Sectional Study
Halovirs A-E, new antiviral agents from a marine-derived fungus of the genus Scytalidium
MEDVi provides unlimited communication with its licensed providers